Lifebit Biotech Ltd, a London, UK–based leading precision medicine software, raised a $60 million Series B funding round.
The round was led by the global investment firm Tiger Global Management. Existing investors Eurazeo, Pentech Ventures, and Beacon Capital also participated.
The Series B funding round will be used to further Lifebit’s global expansion, with a focus on customer success and accelerating the growth of its team, and will crucially enable Lifebit to double down on client success – fueling further support for existing partners, as well as those to come.
Company: Lifebit Biotech Ltd
Round: Series B
Funding Month: September 2021
Lead Investors: Tiger Global Management
Additional Investors: Eurazeo, Pentech Ventures, and Beacon Capital
Company Website: https://lifebit.ai/
Software Category: Enterprise data platforms
About the Company: Lifebit builds enterprise data platforms for use by organizations with complex and sensitive biomedical datasets. Lifebit's patented federated technology securely unlocks access to biomedical data. From providing Trusted Research Environments for national precision medicine programs to enabling pharmaceutical companies to discover new drug targets faster, Lifebit empowers customers to transform how they leverage sensitive biomedical data.